Click here to view online. Add this email to your safelist.

AstraZeneca logo

Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity

6 January 2026

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous (SC) administration of Saphnelo (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo in patients with systemic lupus erythematosus (SLE).

Read more  Read more

RSS Feed  RSS Feed Twitter/X  Follow us on X LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2026

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.